Zolinza
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Cutaneous, CTAGE1 protein, human
Treatment
5 FDA approvals
2 Active Studies for Zolinza
Treatment for
Lymphoma, T-Cell, Cutaneous
What is Zolinza
Vorinostat
The Generic name of this drug
Treatment Summary
Vorinostat (also known as suberoylanilide hydroxamic acid or SAHA) is a medication used to treat cutaneous T cell lymphoma (CTCL), a type of skin cancer. It works by blocking a protein called histone deacetylase. Studies have also suggested that vorinostat may be effective in treating a type of brain tumor called glioblastoma multiforme. More research is being done to determine the effectiveness of using vorinostat in combination with other drugs.
Zolinza
is the brand name
Zolinza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zolinza
Vorinostat
2006
1
Approved as Treatment by the FDA
Vorinostat, otherwise called Zolinza, is approved by the FDA for 5 uses like progressive Cutaneous T-cell lymphoma and Cutaneous T-Cell Lymphoma Recurrent .
progressive Cutaneous T-cell lymphoma
Helps manage progressive Cutaneous T-cell lymphoma
Cutaneous T-Cell Lymphoma Recurrent
Helps manage Cutaneous T-Cell Lymphoma Recurrent
CTAGE1 protein, human
Helps manage Cutaneous T-Cell Lymphoma Recurrent
Lymphoma, T-Cell, Cutaneous
Helps manage progressive Cutaneous T-cell lymphoma
Lymphoma, T-Cell, Cutaneous
Helps manage persistent Cutaneous T-Cell Lymphoma
Effectiveness
How Zolinza works in the body
Vorinostat stops a group of enzymes, called histone deacetylases, from working. These enzymes usually remove acetyl groups from histone proteins. In some cancer cells, there are too many of these enzymes, leading to the suppression of certain cell processes. By blocking the action of these enzymes, Vorinostat helps to restore normal cell function and can help to stop the spread of cancer. The exact way this drug works is not completely understood.
When to interrupt dosage
The prescribed measure of Zolinza is based on the diagnosed condition, such as CTAGE1 protein, human, progressive Cutaneous T-cell lymphoma and Lymphoma, T-Cell, Cutaneous. The quantity of dosage fluctuates, in accordance with the approach of administration recorded in the table underneath.
Condition
Dosage
Administration
Lymphoma, T-Cell, Cutaneous
, 100.0 mg
, Oral, Capsule, Capsule - Oral
Lymphoma, T-Cell, Cutaneous
, 100.0 mg
, Oral, Capsule, Capsule - Oral
CTAGE1 protein, human
, 100.0 mg
, Oral, Capsule, Capsule - Oral
Warnings
There are 20 known major drug interactions with Zolinza.
Common Zolinza Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Vorinostat is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Vorinostat is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Vorinostat is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Vorinostat is combined with Acteoside.
Afelimomab
Major
The risk or severity of adverse effects can be increased when Vorinostat is combined with Afelimomab.
Zolinza Novel Uses: Which Conditions Have a Clinical Trial Featuring Zolinza?
5 active clinical trials are currently assessing the effectiveness of Zolinza in treating Lymphoma, Human CTAGE1 Protein, Cutaneous T-Cell, and Progressive Cutaneous T-Cell Lymphoma.
Condition
Clinical Trials
Trial Phases
Lymphoma, T-Cell, Cutaneous
0 Actively Recruiting
CTAGE1 protein, human
2 Actively Recruiting
Phase 2
Lymphoma, T-Cell, Cutaneous
0 Actively Recruiting
Patient Q&A Section about zolinza
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How is Vorinostat administered?
"Vorinostat is a capsule that is taken orally, typically once a day with food. Your doctor will tell you if you should take it every day or only certain days of the week. You should take vorinostat at approximately the same time each day."
Answered by AI
Is vorinostat FDA approved?
"The U.S. Food and Drug administration approved vorinostat for the treatment of skin manifestations of cutaneous T-cell lymphoma in patients who are unresponsive to other treatments. This is the first time a histone deacetylase inhibitor has been approved for any use in the United States."
Answered by AI
What is zolinza used for?
"ZOLINZA is a drug used to treat a type of cancer called cutaneous T-cell lymphoma (CTCL). CTCL is a cancer that affects the blood cells and causes skin problems. ZOLINZA is used when the cancer gets worse, does not go away, or comes back after you have taken other medicines."
Answered by AI
Is vorinostat chemotherapy?
"Vorinostat is a drug used to treat cancer by inhibiting histone deacetylase."
Answered by AI